Literature DB >> 19845784

Migraine and obesity: epidemiology, mechanisms, and implications.

B Lee Peterlin1, Alan M Rapoport, Tobias Kurth.   

Abstract

Adipose tissue is a dynamic neuroendocrine organ that is involved in multiple physiological and pathological processes, and when excessive, results in obesity. Clinical and population-based data suggest that migraine and chronic daily headache are associated with obesity, as estimated by anthropometric indices. In addition, translational and basic science research shows multiple areas of overlap between migraine pathophysiology and the central and peripheral pathways regulating feeding. Specifically, neurotransmittors such as serotonin, peptides such as orexin, and adipocytokines such as adiponectin and leptin have been suggested to have roles in both feeding and migraine. In this article, we first review the definition and ascertainment of obesity. This is followed by a review of the clinical and population-based studies evaluating the associations between obesity and chronic daily headache and migraine. We then discuss the central and peripheral pathways involved in the regulation of feeding, where it overlaps with migraine pathophysiology, and where future research may be headed in light of these data.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19845784      PMCID: PMC3969571          DOI: 10.1111/j.1526-4610.2009.01554.x

Source DB:  PubMed          Journal:  Headache        ISSN: 0017-8748            Impact factor:   5.887


  71 in total

1.  Agreement of self-reported migraine with ICHD-II criteria in the Women's Health Study.

Authors:  M Schürks; J E Buring; T Kurth
Journal:  Cephalalgia       Date:  2009-03-12       Impact factor: 6.292

2.  Obesity and the risk of myocardial infarction in 27,000 participants from 52 countries: a case-control study.

Authors:  Salim Yusuf; Steven Hawken; Stephanie Ounpuu; Leonelo Bautista; Maria Grazia Franzosi; Patrick Commerford; Chim C Lang; Zvonko Rumboldt; Churchill L Onen; Liu Lisheng; Supachai Tanomsup; Paul Wangai; Fahad Razak; Arya M Sharma; Sonia S Anand
Journal:  Lancet       Date:  2005-11-05       Impact factor: 79.321

3.  Immunological aspects in migraine: increase of IL-10 plasma levels during attack.

Authors:  I Munno; M Marinaro; A Bassi; M A Cassiano; V Causarano; V Centonze
Journal:  Headache       Date:  2001-09       Impact factor: 5.887

4.  Orexin 1 receptor activation attenuates neurogenic dural vasodilation in an animal model of trigeminovascular nociception.

Authors:  P R Holland; S Akerman; P J Goadsby
Journal:  J Pharmacol Exp Ther       Date:  2005-09-13       Impact factor: 4.030

5.  Modulation of nociceptive dural input to the trigeminal nucleus caudalis via activation of the orexin 1 receptor in the rat.

Authors:  P R Holland; S Akerman; P J Goadsby
Journal:  Eur J Neurosci       Date:  2006-11       Impact factor: 3.386

6.  Obesity is a risk factor for transformed migraine but not chronic tension-type headache.

Authors:  Marcelo E Bigal; Richard B Lipton
Journal:  Neurology       Date:  2006-07-25       Impact factor: 9.910

7.  Measures of abdominal obesity assessed for visceral adiposity and relation to coronary risk.

Authors:  A Onat; G S Avci; M M Barlan; H Uyarel; B Uzunlar; V Sansoy
Journal:  Int J Obes Relat Metab Disord       Date:  2004-08

8.  Measures of obesity and cardiovascular risk among men and women.

Authors:  Rebecca P Gelber; J Michael Gaziano; E John Orav; Joann E Manson; Julie E Buring; Tobias Kurth
Journal:  J Am Coll Cardiol       Date:  2008-08-19       Impact factor: 24.094

9.  Migraine prodromes separated from the aura: complete migraine.

Authors:  J N Blau
Journal:  Br Med J       Date:  1980-09-06

10.  Activation of nuclear factor-kappaB by high molecular weight and globular adiponectin.

Authors:  Fred Haugen; Christian A Drevon
Journal:  Endocrinology       Date:  2007-08-16       Impact factor: 4.736

View more
  51 in total

1.  The association of obesity with episodic and chronic migraine.

Authors:  Randolph W Evans; Michelle A Williams; Alan M Rapoport; B Lee Peterlin
Journal:  Headache       Date:  2012-03-08       Impact factor: 5.887

Review 2.  Migraine and metabolism.

Authors:  G Casucci; V Villani; D Cologno; F D'Onofrio
Journal:  Neurol Sci       Date:  2012-05       Impact factor: 3.307

3.  Episodic migraine and obesity and the influence of age, race, and sex.

Authors:  B Lee Peterlin; Andrea L Rosso; Michelle A Williams; Jason R Rosenberg; Jennifer A Haythornthwaite; Kathleen R Merikangas; Rebecca F Gottesman; Dale S Bond; Jian-Ping He; Alan B Zonderman
Journal:  Neurology       Date:  2013-09-11       Impact factor: 9.910

4.  Chronic low back pain, sleep disturbance, and interleukin-6.

Authors:  Kathi L Heffner; Christopher R France; Zina Trost; H Mei Ng; Wilfred R Pigeon
Journal:  Clin J Pain       Date:  2011-01       Impact factor: 3.442

5.  Body composition status and the risk of migraine: A meta-analysis.

Authors:  Bizu Gelaye; Simona Sacco; Wendy J Brown; Haley L Nitchie; Raffaele Ornello; B Lee Peterlin
Journal:  Neurology       Date:  2017-04-12       Impact factor: 9.910

Review 6.  Migraine and obesity: epidemiology, possible mechanisms and the potential role of weight loss treatment.

Authors:  D S Bond; J Roth; J M Nash; R R Wing
Journal:  Obes Rev       Date:  2011-05       Impact factor: 9.213

Review 7.  Migraine: multiple processes, complex pathophysiology.

Authors:  Rami Burstein; Rodrigo Noseda; David Borsook
Journal:  J Neurosci       Date:  2015-04-29       Impact factor: 6.167

8.  Migraine and obesity: moving beyond BMI.

Authors:  Ana Recober; B Lee Peterlin
Journal:  Future Neurol       Date:  2014-01-01

Review 9.  Obesity and Migraine in Childhood.

Authors:  Tal Eidlitz Markus; Irene Toldo
Journal:  Curr Pain Headache Rep       Date:  2018-05-03

10.  Can weight loss improve migraine headaches in obese women? Rationale and design of the Women's Health and Migraine (WHAM) randomized controlled trial.

Authors:  Dale S Bond; Kevin C O'Leary; J Graham Thomas; Richard B Lipton; George D Papandonatos; Julie Roth; Lucille Rathier; Richard Daniello; Rena R Wing
Journal:  Contemp Clin Trials       Date:  2013-03-22       Impact factor: 2.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.